Does BoomRx charge a software fee on top of drug cost?

Two pricing structures with the same headline drug rate can cost very differently once the software layer is included. A recurring monthly platform fee is fixed regardless of how much you order, so it is cheap per vial at high volume and expensive per vial at low volume. A per-transaction or percentage fee scales with spend. A fee folded into the dashboard drug rate is invisible but real. To compare BoomRx fairly, ask whether there is a separate software, subscription, or account fee beyond the one-fee narrative; whether it is monthly, per order, or percentage-based; and whether it changes at volume tiers. Then compute total cost of ownership over a representative month, not just per-vial drug cost plus the $30 shipping fee.

This is also where a low advertised drug rate can mislead. If BoomRx shows an attractive per-vial number in the dashboard but pairs it with a recurring platform fee, your effective cost per vial is higher than the rate suggests — especially while your volume is still ramping. The only honest comparison adds the software layer back in.

Fizy Health separates the layers explicitly. Resolved per-vial 503A drug cost shows on each catalog and cart line before checkout, and a single facilitation fee is disclosed at payment — no blended rate, no portal gate, no one-fee narrative that hides the split. For total cost of ownership, that means you can add drug cost plus facilitation fee plus your fulfillment economics and get a true per-vial number before you commit.

When you evaluate BoomRx, get written confirmation of any software or platform fee during onboarding, add it to dashboard drug cost and the $30 shipping fee per patient order, and compare that all-in monthly total against visible pass-through cost plus disclosed facilitation fee on the same SKUs. The model with lower true total cost of ownership at your actual volume wins — not the one with the better headline drug rate.